{
  "document_id": "adcef29c",
  "zip_file": "fjnw0257.zip",
  "category": "Presentations",
  "content_file": {
    "file_name": "fjnw0257.pdf",
    "file_path": "Presentations/fjnw0257.zip/fjnw0257.pdf",
    "extracted_text": "=== Page 1 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 1 Image 1 (OCR) ===\n& Company EEE Wy\n\nCorporate\nperformance\ndiagnostics\n\nDiscussion document\nMarch 2020\n\n@endo Y L\n\ntd J Wh\neg / f\nOLE DEE T AL ALD PROPR E TARY. FAP SES J\nAng) asi Dns ake gs wltcabsres Dorin seca PR: Kosin Rss ran OC ae Sf bs ff)\nssbety pratt Ct ho\n\nMCK-MAAG-2599303\n\n=== Page 2 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 2 Image 1 (OCR) ===\nKey issues\n\n.\n\nOpioid: Company is facing litigation related to opiaid overuse across many states in US Settled liabilities with\n\npice eit e emitter meee rm ei cre em imrecmre ia!\n\nOklahoma and case coming up with NY state Analyst estimate total potential liability range from USD 0 5B — 4 0B\n\n_ ets SASSER RSS AES ORNSSESS SSEGSESIIEDIEESUESISTEDSNCSOSENSS SEDSISERE SORES AEDST OSSISEN - ASSERSRE NE ENSGRSS SRE SASSI SESE ESESSESENEDS\n\nLegal\n\nRedacted\n\naime tetera terete eerie\n\nRedacted\n\nime tetera terete eee:\n\nime tetera terete eee:\n\nee ee re ere ee et Ee EEE Reem meme meme:\n\nvntovy\n\nMcKinsey & Company\n\nMCK-MAAG-2599303.000001\n\n=== Page 3 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 3 Image 1 (OCR) ===\nSummary\n\n* Endo is well performing operationally with higher margins than peers. However, due to issues related to opioid crisis,\n\nmine e tere ete erate erate ermine\n\netme tetetergieep rere teint ererererereree\n\n5 growth is negative, cash flow did not cover liabilities, debt is below investment grade and\n\n‘company is facing large potential litigation liabilities\n\nite teint eter ete re ere ere ete ee ete a en ee RR ee Rn RR Rn eR nn eR RI RR nn Rn RR eR RR RR ne A RI nn ee a ne ee nie nie eia emia ereieieiereiarermiete\n\nRedacted\n\narea eter eee eee eee eee ee ete ne eR en A ne RR ee Rn RR Re eR nn Re en nn ee ee nn ne nie nie einai e eee ainieieieeia eimieieieeiarermrererereier\n\nMcKinsey & Company\n\n6 September 2020\n\nMCK-MAAG-2599303.000002\n\n=== Page 4 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 4 Image 1 (OCR) ===\nSummary\n\n* Endo is well performing operationally\n\nReet e tee eee eee tate tate imitates\n\nith higher margins than peers. However, due to issues related to\n\nRedacted\n\nopioid crisis,;\n\naise te tege ete re chet ere rime\n\n_.; growth is negative, cash flow did not cover liabilities, debt is\n\nieee tere eter eter rere a ete ee ee a eR ee RR ee A ee RR RnR nn A Rn RR ne RR nn Rn eR Re RR ne A RI ne ee a ee a eee nie eie emia eieeieiereiarermieta,\n\nbelow investment grade and company is facing large potential litigation liabilities\n\nRedacted\n\nieee te eter teeter terete er erate re reterererereie\n\nieee ete eter ermine erate a ere ere ete ee a ere ete ene Re nln ne RR nS A nn A nn eA nn Rn en A ein a ein ete eine nie aia eine a eieiaiaimarereieieiermrmrerereiereres\n\nMcKinsey & Company\n\n6 September 2020\n\nMCK-MAAG-2599303.000003\n\n=== Page 5 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 5 Image 1 (OCR) ===\nEndo’s share price has declined ~90% in last 5 years mainly driven by\n\nlegal challenges and underperformance\n\nEndo share price’\n\nUSD per share\n\nSaaS =a S Sa a SS ae\n\npia = aaa = eae a eae aaa se amre\n\nSev eteiereveteierevererere:\n\n120\n\nMar ‘16: Sued by FTC along\n\nwth others ‘or illegally blocking\n\nRedacted\n\nRedacted\n\nRedacted\n\noe\n\nlower-cos: generic versions of\n\nded drugs Opana\n\neC\n\n:\n\n!\n\n!\n\n|\n\ni. Redacted _j\n\neae,\n\neel aiwienecanienniagcete eiacoseeiscoss.\n\nLeica ierersieievetcieieres =\n\n:\n\nLesaive tee rcte tae rste reverse -\n\nStovatavateteiaiaievainbieveioiaeiot\n\n80\n\nmie te tetera res\n\nieee rere\n\nJun ‘17: Sued by Ohio Asorney General\n\nee ee\n\nalongwith ‘our other pharma companies ‘or\n\n‘heir alleged par: in dnung an opioid and\n\nPrescnpion painkiller overdose epidemic\n\ni\n\n|\n\n:\n\nedacted\n\nViet\n\nRedacted\n\nRedacted !\n\ncmon caiemsncncmiemeael\n\n|\n\n!\n\nthrough aggressive marke'ing ‘ac‘ics\n\niste tetera eter reread\n\n40 -\n\nmie iin ahetetnaieieimnaisienmnany\n\nJun 17: FDA reques's.\n\npain medication, Opana\n\nEndo ‘o rerrove rs opioid\n\nER, ‘ror the marke:\n\n!\n\nLebacananas\n\nta iaiverStaievetctaiciercieicras4|\n\ni\n\nJan 15\n\nJul 15\n\nJan 16\n\nJul 16\n\nJan 17\n\nJul 17\n\nJan 18\n\nJul 18\n\nJan 19\n\nJul 19\n\nJan 20\n\nt\n\n7A bet\n\n77\n\ns:\n\ny\n\nSAP Capla Tet rays s\n\nMcKinsey & Company\n\ni]\n\nMCK-MAAG-2599303.000004\n\n=== Page 6 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 6 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nTne rn SEn ESSER SERS SSE SEnE ESSE SEnSSnESOSnSEnE SES SESERSSNE SESE SERS SESS SEnSSNSSESESERS DSSS SERSRESISEESSRESHSSE SIRENS SESnSSEESOSENSSRESSSSHSEESSRESSSESERISNSSHSESSnS SOSH SERSSSESESSESSSESSSSSERSSNSSHSSESSnSSSSESSnESNSSISSESSnESSSESERSNSSHSnSSESSSSESSSSNSSHSSISSSESHS=NSEnSSNSSOSSRSSRESESSNSTSSSNESESESERESSSSSTESSSESHSnSSESSNSENSESSSNS DS SEnSSRESHSSNSESSSNE SE SnSSEE DESDE SEESSSSOSS\n\n2599303.000005\n\n=== Page 7 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 7 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nTne rn SEn ESSERE SSE SEnE SSDS RENE SESE SERS SESE SERENE SESE SERS SESS SERSSNSSESESEES SSDS SERSnESOSASSRESHSSESERSSNSSESnSSEESNSENSSRESSSHSEESSRESSSNSEnSNSSHSESSnSSNSSESEnSSSESHSSESSSESSSSSERSSSSHSSESSRSSSSSNSSRESNSSISEESSnESHSSESERSSNSSHSnSSRSSNSSSSSSSNSSHSSASSRESHSSNSEnSSNSSOSSESSRSSESSNSTSSEESOSESSRESHSSSSTESSSESHSnSSES ONSEN SESSSNS SS SERSSNSSHSSNSISSSNE SE SnSSEESSSSESERSSNSSISS\n\n2599303.000006\n\n=== Page 8 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 8 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nTne rn SEn ESSENSE SERS nS S REEDS SERS SESS SERSSNE SESE SERS SESS SERSSNSSESESEES DSSS SERSNESHSEESSRESHSSESERSSNSSESSRSSRESNSSESSRSSSSHSSESSRESHSSESSRISNSSHSSESSES SOSH SERSSSSSOSSESSSESSSNSEnSSSSHSSESSnSSSSESSnESNSSISSESSRESSSESERSSESSHSnSSESSSSSSSnSSNSSHSENSSSESHSSNSInSSNSSOSSRSSRSSESSNSTSSSNESESESERESSSSSTESSSESHSnSSESSNSEESESSSNS SS SEnSSNSSHSSNSEnSSNE SE SEnSSES SESS SERSONSSOS\n\n2599303.000007\n\n=== Page 9 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 9 Image 1 (OCR) ===\nEndo's revenue profile has remained flat and declined since 2016 driven\n\nby both Branded and Gx segments\n\nEndo's Revenue evolution by segment, 2014-19, USD bn, as reported\n\nee ae\n\netme e tetera eer rete rer ererereiety\n\n@ Granded >harra i.\n\nPa\n\nRedacted\n\ni @ Genenc 2harra\n\ni\n\ni\n\n:\n\nGrowth (2014-19),\n\nKey takeaway\n\nCAGR SE\n\npietetarerermeeratmermerer arm,\n\n40\n\n:\n\nRedacted\n\n8% p.a\n\n-10% p.a.\n\neine tater e terete rete re rerere!\n\n!\n\n33\n\n35\n\nBranded Pharma portfolio\n\ndeclining, driven by loss of\n\n29\n\n29\n\n29\n\nmarketing exclusivity for\n\ncertain drugs and voluntary\n\nwithdrawal of OPANA® ER\n\nse\n\nfrom the market since\n\nFy201 7\n\n(asa ates a ere eae e atereres 7\n\n26\n\noo\n\n23\n\n03\n\nRedacted\n\n05\n\na3\n\n02\n\nae\n\n20°4\n\n20°9\n\nbeeen eee eee erate ee =\n\nFete CES SOs OES CEs CES SOS OSSEDS CEOS SEE OES SESS OSE CES SUSE CES SU SSS OSE CES SES CSSOES CESSES SSESS CES SUSOSSOSSCES SUS OSS CES SUSE CES SUS OCES SUS OEOSU SOOO a\n\n!\n\nRedacted\n\n!\n\nsoem\n\nSow\n\nen cenicminiascemceiniciemsninscinmimianiaessncmsatmininiaraetaiaiminiarcsmsnininemsniacavmimiaiaessmes:\n\nMcKinsey & Company\n\n)\n\nMCK-MAAG-2599303.000008\n\n=== Page 10 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 10 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnena Sn SEn ESSERE SSE SEnE SSSR SNES SnSERE SESE SERSSnE SESE SERS SESS SERSSnSSESESEES SSSI SERSRESOSESSRESSSESERSSNSSESSnSSSESSSSSSRESSSHSERSSRESESSESERSNSSHSnSSES SSDS SEnSSSESESSnSSSESSSSESERSSSSHSSESSnSSSSESSRESNSSUSSASSRESSSESERSSESSHSESSRSSSSESSSSNSSHSSASSRESHSSNSInSSNSSUSSRSSRSSESSNSTSSSNESESESERESSSSSTESSSESHSnSSESSNSENSESSSNS SS SEnSSNSSHSSNSISSNE SE SnSSESSSSSESEESSSSIS\n\n2599303.000009\n\n=== Page 11 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 11 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnnn Ene rn SEnE ESSERE SSE SEnE SSS SESE RENE SESE SERE SES SE SERENE SESE SERS SESS SERSSNSSESESEES SSDS SERSNESOSEESSRESHSSESEnSSNSSESnSSRESNSSESSRESSSHSSESSRESSSESERESNSSHSRSSSSSSSNSERSSSESOSSESSSESSSISERSSSSHSSESSnSSSSSSSSESNSSISSESSnE SSSI SERSSNSSHSESSRSSHSSESSnSSNSSHSERSSEE SSSA STnSSNSSOSSRSSRSSESSNSTSSNESESESERESSSSSTESSSESHSnSSES ONSEN SESESNE SS SERSSRSSHSSNSESSNE SE SRSSROSSSSESEESOSSOS\n\nAAG-2599303.000010\n\n=== Page 12 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 12 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnner EnE rn SEnE ESSERE SSE SEnE SSDS RENE SOS nSEnE SESE SEnSSnE SESE SERS SESS SERSSnS SES EESEES DSSS SERSRESOSEESSEESESSE SERENE SESSnSSRESNSSESSRESSSHSSESSRESSSESERSNSSHSESSRSSSSNSERESSS SOS SESSSESSSSSERSSSSHSSESSRSSSSSESSnSSNSSISSESSRESSSESERSSNSSHSnSSRSSOSSESSRSNESHSSRSSSESH SSN SInSSNSSOSSRSSRSSESSESTSSSNESESESERE SSDS STESSSESHSnSSES SSE SSSSSNS SS SERSSESSHSSNSINSNE SE SnSSROSSSESERSSSIS\n\nAAG-2599303.000011\n\n=== Page 13 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 13 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnena Ene rn SEnE ESSERE SSE SEnE SSE SERENE SESE SEnE SES SE SERENE SESE SERS SESS SERSSNSSESESEES SSDS SERSRESHSNSSRESHSSESERSNSSHSnSSEESSENSSRESSSHSSESSRESSSESERSNSSHSESSESSISSNSERSSSSSOSSnSSSESSSSSERSSSSHSSESSRSSSSESSSSSNSSISEASSRE SSSI SERSSESSHSESSESSHSSESSSSNSSHSEISSEESHSSNSInSSNSSOSSRSSRSSESSNSTSSSNESESESERESSSSSTSSSSESHSnSSES ONSEN SESSSNS SS SERSSNSSHSSSSISSNE SE SnSSROSSSSESEEDOSSISS\n\nAAG-2599303.000012\n\n=== Page 14 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 14 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nTne nE rn SEnE ESSE SSE SEnE SSDS RENE SESE SERS SESS SERSSNE SESE SSNS SESS SERSSnSSESEASEEE SSDS SSRSNESISEESSRESESSESIRSSNSSESnSSRESSESSSRSSSSHSSESSRESSSSESERSNSSHSESSnSSHSSN SERENE SO SSESSSESSSSSEnSSNSSHSSESSRSSSSSSSSRESNSSISSESSRESHSSESERSSNSSHSnSSRSSSSESSSSNSSHSSASERESHSSNSInSSNSSOSSRSSRSSESSESTSSSNESESESERESSSSSSTSSSSESHSnSSES SSE SESISNE DS SEnSSRESHSENSISSNE SE SnSSROSSSSESEESSSOSS\n\nAAG-2599303.000013\n\n=== Page 15 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 15 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnner ncn nS SERENE SSE SERE SSDS nSEnE SESE SERE SES SE SERENE SESE SSnSSOSSSSERSSNSSESESEES DSSS SERESNESHSEESSRESHSSESERSSNSSESnSSRESSSSSSRSSSSSHSSESSRESHSSESERSNSSHSnSSRSSHSSHSERSSSESOSSESSSESSSSSERSSSSHSSESSRSSSSSSSSESNSSISEASSRE SSSI SERSSNSSHSESSRESSSESSnESNSSHSSISSEESNSSNSEnSSNSSOSSRSSRSSESSESTSSNESESESERESSSSSSTESSSESHSnSSES SSSA SSSESNS DS SnSSRSSHSSNSEnSSNE SES ERSSRS DESDE SEESNSSIS\n\nAAG-2599303.000014\n\n=== Page 16 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 16 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnner rn SEn ESSERE SSE SERE DOSES RENE SESE SEnE SESE SERENE SESE SSNS SESS SERSSnS SES EESEEE DSSS SSRSRESOSEESSRESHSSESERSSNSSESnSSEESSSNSSRSSSSHSSESSRESSSESERSNSSISESSRSSSSESERSSSESOSSESSSESSSSSERSSSSHSSESSRSSSSNSSnESNSSESSASSnESSSESERSSESSHSESSRSSSSESSSSNSSHSEISSRESHSSNSInSSNSSOSSnSSRSSESSNSTSSSnESOSESERESSSSSTESSSESHSnSSES SSSA SESESNS SS SEnSSNSSHSSNSESSNE SE SnSSRO DESDE SEESOSSOS\n\nAAG-2599303.000015\n\n=== Page 17 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 17 Image 1 (OCR) ===\nre\n\nEndo also has large potential litigation liabilities up to USD iresactes:\n\neine terete\n\nEstimate\n\nLiability\n\nOpioid\n\n\"If we consider Oklahoma to be a “typical” state (28th in population and 29th in GDP). Endo’s settlement\n\nimplies a nationwide liability around $500M.“ — Gabelli. Jan 14°, 2020\n\n\"We estimate a fair value range of S2-4 based on our DCF (10% WACC. -1% terminal). using ~$3-4B\n\nopioid charges paid over 10 years.” — Guggenheim, Nov 5\", 2019\n\nnS SSS SSE\n\nRedacted\n\nLinea te eee eee ee ete te eter eee a erate a ete ere ere a ete ere ete ee en ne ee nie nn nn en a nn ee ee a nin nie ete ein mia emia ein eie eam eiereieiereimrerereiees =\n\nsor\n\nssp\n\nvila og Areal:\n\nrhe\n\nvt\n\nMcKinsey & Company\n\n7\n\nMCK-MAAG-2599303.000016\n\n=== Page 18 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 18 Image 1 (OCR) ===\nOpioid portfolio currently consists of Percocet” that contributes\n\n~14% of Branded Pharma and 4% of company revenue\n\n\"PERCOCET™. which is an opioid analgesic approved for the treatment of moderate-to-moderately-severe pain\n\nThe Company's pain products, including opioid products. are managed as mature brands and are not and have not been actively promoted for years. In\n\nDecember 2016, the Company announced the elimination of its entire U.S. pain product field sales force\n\nGeneric Pharmaceuticals The Generic Pharmaceuticals segment includes a product portfolio of approximately 150 generic prescription product families\n\nincluding solid oral extended-release. solid oral immediate-release. liquids, seni-solids, patches (which are medicated adhesive patches designed to deliver the\n\npharmaceutical through the skin), powders. ophthalmics (which are sterile pharmaceutical preparations administered for ocular conditions) and sprays and\n\nincludes products in the pain management. urology. central nervous system disorders, immunosuppression, oncology. women’s health and cardiovascular disease\n\nmarkets, among others\n\n- 10K 2019\n\nRevenue in USO M\n\n2019\n\nPercocet\n\n116\n\nBranded Pharma\n\n855\n\nPercocet as % of Branded Pharma\n\n14%\n\nEndo total revenue\n\n2.914\n\nPercocet as % of Endo total revenue\n\n4%\n\nsor\n\nwn tov)\n\n18\n\nMcKinsey & Company\n\nMCK-MAAG-2599303.000017\n\n=== Page 19 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 19 Image 1 (OCR) ===\nSummary\n\n. Endo | is well performing operationally with higher margins than peers. However, due to issues related to opioid crisis,\n\npice rete eet ere ele ete eter e te ar ebereiey\n\nRedacted\n\nLinen ee ee LE ee eee\n\nigrowth is negative, cash flow did not cover liabilities, debt is below investment grade and\n\niste teint ete te eee erent eee ere re ee eR RR RR ee Rr RR nn A nn RR RR RR Re eR RR RR eR Rn Rn RR ne nn eee ni ee eee eimai ere ernie erie\n\ncompany is facing large potential litigation liabilities\n\nRedacted\n\niin tetera erate reer rere reer ererereierereiereieie\n\narea tee erate eee eee ete ee ee ee ee Re ee Re eR RR RR ee A en A Re eR en eR ee en a ee ee eine eieeiaieinaeinieiaeineeieeiaemaeieeaeimeeieeerered\n\nMcKinsey & Company\n\n19\n\n6 September 2020\n\nMCK-MAAG-2599303.000018\n\n=== Page 20 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 20 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nTne nE rn SEnE ESSE SSE SEnE SSDS RENE SESE SERS SESS SERSSNE SESE SSNS SESS SERSSnSSESEASEEE SSDS SSRSNESISEESSRESESSESIRSSNSSESnSSRESSESSSRSSSSHSSESSRESSSSESERSNSSHSESSnSSHSSN SERENE SO SSESSSESSSSSEnSSNSSHSSESSRSSSSSSSSRESNSSISSESSRESHSSESERSSNSSHSnSSRSSSSESSSSNSSHSSASERESHSSNSInSSNSSOSSRSSRSSESSESTSSSNESESESERESSSSSSTSSSSESHSnSSES SSE SESISNE DS SEnSSRESHSENSISSNE SE SnSSROSSSSESEESSSOSS\n\nAAG-2599303.000019\n\n=== Page 21 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 21 Image 1 (OCR) ===\nFuture cash flows from operations would be used up for litigation\n\nand interest charges and debt repayments\n\nCumulative cash flow, FY2020-24, USD bn\n\nUpside case\n\nDownside case\n\npotent ernie eter rete eter rete mieten ete rm eter mien tmr minim emir mie:\n\nCFO betore interest i\n\nete eee ere eee ee ee ete a eee emp eee a eee eee ete eie eer ererermiere!\n\nRedacted\n\nAssumptions:\n\news e sateen sree sese a ere rata saree se rsraa saree sererernsy\n\n&changesinwe '\n\ni\n\nmie ietete terete teen\n\nLrigation charges\n\ni\n\ni\n\nRedacted\n\netme teeter erate teeter terete ete eter eterelee ere erereterereierereetelereiererererereres|\n\n[a\n\n_\n\nie a sese se a tereeteta aerate ie serete esate a tees ateeiern\n\nOpioid litigation liability estimated to range from\n\n: Redacted !\n\nUSD 500M In Upside case to USD 4.0B in Downside\n\ncase (based on analyst reports), assumed to be\n\niesece eter reese res |\n\n!\n\nLa faveietesereietesas, a\n\nTee eee ee cae saseteseietesniereseteiesmsnieiesnieinsy\n\nrepaid by FY2024\n\nRedacted !\n\nit\n\nfoe seie rete tere se, 7\n\nit\n\nit\n\nRedacted\n\nit\n\nit\n\nit\n\nRedacted\n\nit\n\nit\n\nit\n\nit\n\nit\n\n1 Crete re ere e re ere rere ete erate aimee mre reres mr ererm mre res =\n\nfp pina erie lei erie erate aise rns (ore rete sarees sopereioloreresosarer,\n\ni\n\nota Simian ieinra es imine Simin re sre iere siete\n\nRedacted\n\njetore sei eta ne sntat areata aieatate rn ietatere erate te eiatamieiataieieret=ss\n\nMcKinsey & Company\n\n21\n\neine tee eter ete te erate a ete a ere ee ete ere ete a nie ete nin en A Rn RI nn RR eR Rn RR Rn RI eR A RI RIA nS A RI RR eR A RR Re RR nn en ne A nn en a nia nin mie a nie nie mieie mim nimi miereimie erm miermrmimimmienty\n\nRedacted\n\nieee teeter rete re erate eee eee ere ete ere en a eR Re eR Re eR RI RR eR ne RI RR RR RR nn A Rn Re SR RR RR eR Rn RR ee A ne A ee A ne ne eee nie nin nee eimai mie eieeieremimierereierereinreree\n\nMCK-MAAG-2599303.000020\n\n=== Page 22 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 22 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnner Ene rn SEnE ESSENSE SERS SnS SESE nEnE SESE SERE SES SESERSSnE SESE SERS SESS SERSSnSSESESEES SSDS SERSNESOSEESSRESESSESERSSNSSESnSSRESSSESSRSSNSSHSSESSRESHSSESERSNSSHSRSSESSISSESERESSESESSESSSESSSSISERSSNSSHSSESSRSSSSSESSRESNSSISEESSnESSSESERSSNSSHSESSRESOSSSSSSSNSSHSSISSRESHSSNSInSSNSSOSSRSSRSSESSNSTSSSNESESESERSSSSSSTESSSE SHS nSSES SSSA SESSSNS SS SRSSNESHSSNSISSNE SE SESSEESSSESESOSSIS\n\nAAG-2599303.000021\n\n=== Page 23 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 23 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnena rn SEnE ESSERE SSE SEnE SSDS RENE SESE SERE SES SESERSSNE SESE SERS SESS SERSSNSSESESEES SSDS SSRESRESUSEASSRESHSSISERSSNSSUSSnSSEESSSSSSRSSSSHSSESSRESHSSESERISNSSHSnSSESSSSESERSSSE SS SESSSESSSESERSSNSSHSSnSSnESSSSSSSSSNSSHSSESSNESSSESERSSESSHSnSSRESSSSSSnSNSSESSISSRESNSSASInSSNSSUSSRSSRSSESSNSTSSSNESUSESSRESSSSSSTESSSESHSnSSES SSE SESSSNS DS SEnSSNESHSSNSESSSNE SE SnSSEE DESDE SEEEONSSISS\n\nAAG-2599303.000022\n\n=== Page 24 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 24 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nTne nnn rn SEnE ESSER ENED S SERS nS SESE n ERE SOS SERS SESS SERENE SESE SERS SESS SEESSNSSESnSEES SSDS SERSSRESOSEESSRESESSESERSSNSSHSnSSRESSSSSSRESSSHSSESSRESSSESERSNSSISESSnS SOSH SEnSSSESESSESSSESSSISERSSSSHSSESSnESSSHSSSSSNSSISEESSRE SSSI SERSESSHSESSRSSSSSSSnSNSSHSSASSRESHSSNSEnSSNSSUSSRSSRSSESSESTSSSNESESESERESSSSSTESSSESHSnSSES ONSEN SSSISNS SS SEnSSRSSHSSNSISSSNE SE SnSSEE DESDE SEEESSSISS\n\n2599303.000023\n\n=== Page 25 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 25 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnner ne rn SEnE ESSENSE SERS nS SEn SNE SOS SERS SES SESERSSNE SESE SERS SESE SERSSNSSESESEESSOSSESERESRESOSEESSRESSSESIRSSNSSHSnSSRESSSESSRESSSSHSERSSRESSSESSnSNSSHSSRSSRSSSSESEnSSSESESSESSSESSSSSEnSSNSSHSSESSRSSSSSSSSRESNSSUSEASSnESSSSE STRESS SH SESSRS SSDS SSSSNESHSSASSRESNSSNSInSSNS SUS SRSSRESESSNSTSSSNESESESSRESSSSSTESSSESHSnSSESSSEESSSISNS SS SERSSRSSHSSNSISSNE SE SnSSEESSSESERSONSSIS\n\nAAG-2599303.000024\n\n=== Page 26 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 26 Image 1 (OCR) ===\nAnalysts are concerned about Endo's ongoing opioid litigations,\n\nsignificant levels of leverage and growth outlook\n\nope Oe aie ere ie ere eet erate ial miata mre reese aterm rere ieee cere rs\n\n@ We are becoming more positive on ENDP from an opioid standpoint,\n\nsaw teaea aerate tater caravan!\n\nSOM ia iai eine ta eimai are im retarel sinter crave vatitaie tary\n\n;\n\nRedacted\n\nRedacted\n\nieee eter eee te erate a ere ere ete ee a ere ete ee a nie nie ere a a emia eee en nate amie mma a mnie mma mma minim mmm minim imimimimns\n\n|\n\n|\n\nGabelli, 14\" Jan 2020\n\nore l a ere alae ie esare ese iateas ese 1are eles e.ere le ersten. e.clatare ie esa elerescreieseisrecetese a eielaersrease.eresereresey\n\npS ntareeeiatavene i atorere intone inten\n\n©\n\nRedacted\n\narea etn: ewe vere\n\ni\n\nVee ee ee ee ee ete eter ere ee eter niet et ete te mie er mieten ete ni mieten mieten miata tar mietm mein imi am tmrm mim rms\n\nRedacted\n\n+ Redacted |\n\nENDP’s high leverage\n\nand ongoing opioid litigation/headline risk add unique risks that are challenging to handicap and have weighed on the stock\n\nRBC capital markets, 5\" Nov 2019\n\naisle Siete ei ie te Sie aA ela eie tale Shia ae ieee Siete Siete ise lae ial eisieie;\n\na en ee ee\n\nRedacted\n\nSo ee a ee ne\n\n‘However, we continue to expect this dynamic to be\n\novershadowed by the ongoing opioid saga, which in our view remains a very significant risk given the company's branded\n\nRien Sinaia iar lace le Died ant Bij aib Serer e areata eae le mice ia, DladS ep aiuie le tia eta aA emetatatelaelaleisretaceleeiesnie\n\n!\n\ncotdvetere bes rerarareia ie ere terete\n\nopioid portfolio/mkt share F’\n\ni\n\naise teint eterna ete eter e rere ete ere ete a ere ere aie ere eie eee eee nie aie area eimai aieeieiemieiermimierermimreres\n\nRedacted\n\nlataiasavetntaieretala erate state tetete:\n\nJP Morgan, 5 Nov 2019\n\n1\n\nMcKinsey & Company\n\n26\n\nMCK-MAAG-2599303.000025\n\n=== Page 27 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 27 Image 1 (OCR) ===\nAnalysts see upside driven by Endo's generic and sterile injectables\n\nportfolio and CCH future potential\n\n@ We are maintaining our Buy rating as we see significant potential upside if ENDP continues to execute, although we expect\n\ninvestors to remain cautious in the near term given continued uncertainty regarding potential opioid liability and the recently\n\nannounced CEO change\n\nSunTrust Robinson Humphrey, 11°? Nov 2019\n\n(epee ia aia ieie ara aia mre ae areata araiase.eyacass-are\n\n@ we expect investor focus to begin to increasingly dig into two issues (beyond opioids) i\n\nole eiataie lalate cialele a bicielatalele cleieie. ciitS lars aia etSiaiate Steele SSIS alah ciate aie. SiseS les iOtas\n\nRedacted\n\n|\n\nRedacted\n\n!\n\n|\n\nbee ee ee ee ee ete ete eee ete a ere ere ete a ere ere ete ere aie a ete eer e aie mie a ere a emia eee a ern a a a arm apermrmiarmrmiaimimrmimrmrmrmimrmrmrmrmemrmrmemed\n\nRBC capital markets, 5'® Nov 2019\n\ninte tater eter eee eter ete ete eee ee ete ee a ee ete ee Rn nein nn A ne nn nn Re ne a ne a nie eine na ein mini mie nimi mia ernie ere miami eieieie\n\n@:\n\nRedacted\n\n|\n\nViavevcintavatStateietcin iste cieieletcveatetecietaterctelaierciaiaratSeisietcinietatcieiletatcvetelasietatercieiseiciaisreatdiaisietcieistatciaietesvetalecieiatectetevercs a\n\n|\n\n1\n\nMcKinsey & Company\n\n27\n\nMCK-MAAG-2599303.000026\n\n=== Page 28 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 28 Image 1 (OCR) ===\nSummary\n\nEndo\n\nwell performi fe] operationally with higher margins than peers. However, due to issues related to opioid crisis,\n\na\n\nRe\n\nfed\n\nDee ete eee ere Sere ere eee eee\n\n; growth is negative, cash flow did not cover liabilities, debt is below investment grade and\n\n‘company is facing large potential litigation liabilities\n\netme teeter erate eee a ere ee ete ere en ee eR Re RR en RR RI RR nn A RI RR en eR Rn RR ne A nn eR ne A nn en eee nin ee eee einen eieiaieimimiermimieinieiay\n\nRedacted\n\nite teint ere rete eter eet a ete ere ete a ete ere ee a nie nn RR en Rn Rn Re eR nn RR en A nn ne ne A nine ee nie ein ein a nie nineteen mia eimmieieeimierereiereres\n\nMcKinsey & Company\n\n28\n\n6 September 2020\n\nMCK-MAAG-2599303.000027\n\n=== Page 29 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 29 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnen rn SEnE ESSENSE SEnE SSS SE REEDED En SEnE SES SE SERENE SESE SERS SES EESERSSNSSESASEES DSSS SERSNESOSESSRESHSSESERSSNSSESnSSRESNSSSSSRESSSHSSESSRESSSESEnSNESHSESSES SSSA SERSSSESESSESSSESSSNSERSSSSHSSESSnSSSSSESSRESNSSHSSASSnESHSSESEnSSESSHSESSRESHSSESSnSNSSHSSnSSEESHSSNSInSSNSSOSSESSRESESSNSTSSNESESESERESSSSSSTESSSESHSnSSESSSSESSSSSNS SS SEnSSNSSHSSNSISSSNE SE SnSSEESSSSESESSNSSOSS\n\n2599303.000028\n\n=== Page 30 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 30 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nTne nnn rn SEnE ESSER ENED S SERS nS SESE n ERE SOS SERS SESS SERENE SESE SERS SESS SEESSNSSESnSEES SSDS SERSSRESOSEESSRESESSESERSSNSSHSnSSRESSSSSSRESSSHSSESSRESSSESERSNSSISESSnS SOSH SEnSSSESESSESSSESSSISERSSSSHSSESSnESSSHSSSSSNSSISEESSRE SSSI SERSESSHSESSRSSSSSSSnSNSSHSSASSRESHSSNSEnSSNSSUSSRSSRSSESSESTSSSNESESESERESSSSSTESSSESHSnSSES ONSEN SSSISNS SS SEnSSRSSHSSNSISSSNE SE SnSSEE DESDE SEEESSSISS\n\n2599303.000029\n\n=== Page 31 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 31 Image 1 (OCR) ===\nERR ES\n\nRedacted\n\nTn enn EnEDSnSEnE ES EESE RSENS SE SESEnE SE SSESEnENESESnSEnSSESSISESSSNSSESESSRSSHSSISSRSSNSSESEISSESSISSISSRSNSSHSIESSEESHSSNSSRSSNSSESSNSSEESHSENSSRSNSSHSSRSSRESHSSNSERISNSSHSInSSESSHSSNSERSNSSHSSNSSSESISSNSENSESSHSNSSESSSSNSSRESNSSHSNSSEESHSSESERSSESSHSESSESSHSSISSNSSNSSHSESERESHSENSERSSNSSHSSRESEOSESENSTSSSNESHSESERESNSSNSTEESNESHSTRSSESSHSENSESESNSDSSEnSSEOSHSSISISSSNE DE SRSSES DESDE SESSNSSO\n\n2599303.000030\n\n=== Page 32 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 32 Image 1 (OCR) ===\nERR ES\n\nRedacted\n\nCnn nen Ener nSEnE SEES RSENS SE SnSEnESSSESERSnESESnSSRSSESSESERSSNSSESEESSRSSHSSSSTRESNSSESENSSESSISSISSRESNSSHSIRSSEESHSSNSORSSNSSHSSNSSEESHSENSSRSSNSSHSSRSSEESHSSNSERISNSSHSIRSSESSHSSNSERSSSSHSSNSSSOSHSSNSENSSNSSHSNSSEOSISSNSSRSSNSSHSNSSEESHSSESERSSNSSHSIESERSSHSSISSNSSNSSHSIESERESHSENSINSNSSHSnESEOSESSESTSSSNESHSESEROSNSSNSTSSSNESHSRSSEOSNSENSSNESNSDHSInSSEESHSSISISSSNS SE SERSSESSHSEESERSNSSISS\n\n2599303.000031\n\n=== Page 33 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257\n\n=== Page 33 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnner EnE rn SEnE ESSERE SSE SEnE SOS SESE RSE SOSnSEnE SES SE SERENE SESE SERS SESS SERSSNSSESASEES SSSI SERSRESHSASSRESESSESERSSNSSESnSSRESNSSESSRESSSHSERSSRESHSSESERISNSSHSnSSESSISSNSERSSSSSHSnSSSESSSSSERSSSSHSSESSRSSSSSNSSRSSNSSISEASSnE SSSI SERSSESSHSESSRSSSSESSSSNSSHSESSSSESHSSESInSSNSSUSSRSSRSSESSNSTSSSNESESESSRESHSSNSTESSSESHSnSSES SSE SSSSSNS SS SEnSSRESHSSNSESSNE SE SnSSEE DESDE SEESNSSISS\n\n2599303.000032",
    "extraction_method": "pymupdf+enhanced_ocr",
    "text_length": 25934,
    "errors": [],
    "success": true
  },
  "metadata_file": {
    "file_name": "fjnw0257-info.pdf",
    "file_path": "Presentations/fjnw0257.zip/fjnw0257-info.pdf",
    "extracted_text": "=== Page 1 ===\nnull - fjnw0257 - Downloaded 31/03/2025 11:09:44 AM\nDocument Information\nTitle: PowerPoint Presentation\nURL: https://www.industrydocuments.ucsf.edu/docs/fjnw0257\nAuthor: Manoharan Dillibabu\nDocument Date: 2020 March 02; 2020 May 11\nType: Presentation\nGenre: Microsoft Office PowerPoint Open XML Format\nPages: 33\nID: fjnw0257\nCollection: McKinsey Documents\nDrug: Oxycodone; Oxymorphone\nAvailability: public; no restrictions\nBates Number: MCK-MAAG-2599303\nRedacted: yes\nDate Added UCSF: 2022 June 06\nCite This Document\nAuthor. Title. Date. Year. Collection. Source. https://www.industrydocuments.ucsf.edu/docs/[ID]\nManoharan Dillibabu. PowerPoint Presentation. 2020 March 02; 2020 May 11. McKinsey \nDocuments. Unknown. https://www.industrydocuments.ucsf.edu/docs/fjnw0257",
    "extraction_method": "pymupdf+enhanced_ocr",
    "text_length": 784,
    "errors": [],
    "success": true
  },
  "processed_at": "2025-06-12T12:06:34.963775"
}